Suchergebnisse - "Roeker, Lindsey E"

PubPharm (7)

1

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings : Results From a Multi-Center International Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Shadman, M. | Manzoor, B. | Sail, K. | +28

2

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Haematology | 2021

von Soumerai, J. | Mato, A. | Dogan, A. | +43

CommentIn: Lancet Haematol. 2021 Dec;8(12):e864-e865. - PMID 34826404

3

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN) : a phase 1/2 study

enthalten in: Lancet (London, England) | 2021

von Mato, A. | Shah, N. | Jurczak, W. | +41

CommentIn: Lancet. 2021 Mar 6;397(10277):855-857. - PMID 33676615

4

Outcomes of COVID-19 in patients with CLL : a multicenter international experience

enthalten in: Blood | 2020

von Mato, A. | Roeker, L. | Lamanna, N. | +59

CommentIn: Blood. 2020 Sep 3;136(10):1115-1116. - PMID 32882019

5

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

enthalten in: Blood advances | 2020

von Roeker, L. | Dreger, P. | Brown, J. | +22

6

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Roeker, L. | Fox, C. | Eyre, T. | +33

7

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial

enthalten in: American journal of hematology | 2018

von Mato, A. | Roeker, L. | Allan, J. | +27

1
[1]